CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma

被引:35
作者
Ihara, Fumie [1 ,2 ]
Sakurai, Daiju [1 ]
Horinaka, Atsushi [1 ]
Makita, Yuji [1 ]
Fujikawa, Akira [1 ]
Sakurai, Toshioki [1 ]
Yamasaki, Kazuki [1 ]
Kunii, Naoki [1 ]
Motohashi, Shinichiro [2 ]
Nakayama, Toshinori [3 ]
Okamoto, Yoshitaka [1 ]
机构
[1] Chiba Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan
[2] Chiba Univ, Grad Sch Med, Dept Med Immunol, Chiba, Japan
[3] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan
关键词
Head and neck cancer; Regulatory T cell; Prognosis; Biomarker; Immunotherapy; SUPPRESSOR-CELLS; IMMUNE-SYSTEM; LUNG-CANCER; TUMOR MICROENVIRONMENT; BREAST-CANCER; TGF-BETA; NIVOLUMAB; PROGRESSION; DOCETAXEL; MELANOMA;
D O I
10.1007/s00262-017-2021-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although regulatory T cells (Tregs) are thought to play an important role in immune suppression, their clinical significance in head and neck squamous cell carcinoma (HNSCC) is unclear. A recent study reported Tregs could be divided into functional subsets based on the expression of CD45RA and Foxp3. Method The frequency of circulating Treg subsets was analyzed in patients with HNSCC and compared with the frequency in patients with benign tumors. The association of Treg subsets with the frequency of lymphocyte subsets, status of progression, clinical course, and prognosis were also examined. Results The frequency of CD4(+)Foxp3(+) Tregs was comparable between HNSCC patients and age-matched benign tumor patients; however, CD45RA(-)Foxp3(high) Tregs were significantly increased in HNSCC patients, in particular those with advanced stage tumors. The high frequency of CD45RA(-)Foxp3(high) Tregs correlated with a poor prognosis and the low frequency of CD45RA(-)Foxp3(high) Tregs before treatment showed a better clinical outcome, even in patients with advanced stage tumors. CD45RA(-)Foxp3(high) Treg numbers were decreased after intensive treatments; however, Treg numbers recovered in the early stages of recurrent cases, even before the clinical manifestation. Conclusion CD45RA(-)Foxp3(high) Tregs are associated with the clinical course of HNSCC and might be a new target for treatment and an early marker of tumor recurrence in HNSCC patients.
引用
收藏
页码:1275 / 1285
页数:11
相关论文
共 41 条
[1]   T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer [J].
Albers, A. E. ;
Strauss, L. ;
Liao, T. ;
Hoffmann, T. K. ;
Kaufmann, A. M. .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,
[2]   SERUM IL10 AND CIRCULATING CD4+CD25high REGULATORY T CELL NUMBERS AS PREDICTORS OF CLINICAL OUTCOME AND SURVIVAL IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA [J].
Alhamarneh, Osama ;
Agada, Frank ;
Madden, Leigh ;
Stafford, Nicholas ;
Greenman, John .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2011, 33 (03) :415-423
[3]   Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells [J].
Alizadeh, Darya ;
Larmonier, Nicolas .
CANCER RESEARCH, 2014, 74 (10) :2663-2668
[4]   Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].
Alvaro, T ;
Lejeune, M ;
Salvadó, MT ;
Bosch, R ;
García, JF ;
Jaén, J ;
Banham, AH ;
Roncador, G ;
Montalbán, C ;
Piris, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1467-1473
[5]   Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers [J].
Badoual, C ;
Hans, S ;
Rodriguez, J ;
Peyrard, S ;
Klein, C ;
Agueznay, NE ;
Mosseri, V ;
Laccourreye, O ;
Bruneval, P ;
Fridman, WH ;
Brasnu, DF ;
Tartour, E .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :465-472
[6]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[7]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[8]   CANCER - A BIOLOGICAL APPROACH .1. THE PROCESSES OF CONTROL [J].
BURNET, M .
BRITISH MEDICAL JOURNAL, 1957, 1 (APR6) :779-786
[9]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[10]   Immune Suppression in Head and Neck Cancers: A Review [J].
Duray, Anaelle ;
Demoulin, Stephanie ;
Hubert, Pascale ;
Delvenne, Philippe ;
Saussez, Sven .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,